Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO), a genetic medicines company, announced that its CEO, Geoff McDonough, will join a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 3:00 p.m. ET. A live webcast will be accessible via the company's investor website, with a replay available for 30 days post-event. Generation Bio focuses on non-viral gene therapies, utilizing innovative technology such as closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles (ctLNP) to provide solutions for rare diseases.

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 20^th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:00 p.m. ET.

A live webcast of the fireside chat will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is engineered to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visit www.generationbio.com. 

Contact:

Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420

Media 
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275

Stephanie Simon 
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

FAQ

What is the date and time of Generation Bio's fireside chat at the Needham Virtual Healthcare Conference?

Generation Bio's fireside chat is scheduled for April 15, 2021, at 3:00 p.m. ET.

Where can I watch the live webcast of Generation Bio's event?

The live webcast can be viewed on the investor section of Generation Bio's website.

What technologies does Generation Bio use in its gene therapy?

Generation Bio utilizes closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles (ctLNP) in its gene therapy platform.

How long will the replay of Generation Bio's conference chat be available?

The replay will be available for 30 days following the event.

What is the focus of Generation Bio's genetic medicines?

Generation Bio focuses on creating non-viral gene therapies for rare and prevalent diseases.